AR and posterior cortical atrophy: V-ATPase inhibitors may thus lead to new treatments relevant for patients that have PCa tumors containing mutant versions of AR, as V-ATPase inhibition represses AR activity at the transcriptional level, overriding any treatment resistance due to protein mutations.